

Resolution

of the Federal Joint Committee (G-BA) on a Non-amendment
of the Pharmaceuticals Directive (AM-RL):
Annex XII – Benefit Assessment of Medicinal Products with
New Active Ingredients according to Section 35a SGB V
Odronextamab (relapsed or refractory follicular lymphoma, at
least 2 prior therapies);
restriction of the authority to supply care

of 6 March 2025

At its session on 6 March 2025, the Federal Joint Committee (G-BA) resolved not to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No 49a of 31 March 2009), as last amended by the publication of the resolution of DD. Month YYYY (BAnz AT DD.MM.YYYY BX), with regard to a restriction of the authority to supply care, as the consultation procedure for the requirement of routine data collection and evaluations for the active ingredient odronextamab in the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy was suspended by resolution of the G-BA of 6 March 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 6 March 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken